Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tesaro, AnaptysBio collaborate on immune checkpoint inhibitors

This article was originally published in Scrip

Executive Summary

Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.

You may also be interested in...



GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication

GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.

Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer

The company, encouraged by positive Phase I data from a trial testing the PARP inhibitor niraparib in combination with Merck's PD-1 inhibitor Keytruda in recurrent ovarian cancer, plans to initiate a larger trial by the end of the year or early in 2018.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Topics

Related Companies

UsernamePublicRestriction

Register

SC024746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel